Tag Archive for: drug discovery

Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company

/in

San Francisco, California – Yavne, Israel – July 14th, 2026 – Genopore, the next-generation proteomics company developing the first semiconductor based optical nanopore technology platform with AI/ML analysis for direct single protein molecule identification and digital quantification, today announced the appointment of life science leader Rey Mali as its new Chief Executive Officer, with immediate […]

Read more

DaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaboration

/in

Dalton is a drug discovery platform integrating agentic AI, human expertise, and experimental data, into one continuous learning engine Announces collaboration with Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), as a client London, UK – 4 June 2026 – DaltonTx, the intelligence backbone for modern drug discovery: connecting AI, human expertise and […]

Read more

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

/in

Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer Financing supports Ona’s transition […]

Read more

Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics

/in

Collaboration combines Bonito’s proprietary functional delivery data engine and ligand discovery platform with DaltonTx’s adaptive AI technology to accelerate precision oligotherapeutic delivery, beginning in the CNS Waltham, MA and London, UK – May 27th, 2026 – Bonito Biosciences (“Bonito”), a biotechnology company building the data foundation for programmable oligotherapeutic delivery, and”) DaltonTx, the intelligence backbone […]

Read more

Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders

/in

New prestigious grants support Lario’s unique portfolio of calcium channel programmes Indication expansion into Parkinson’s disease, and PTSD (post-traumatic stress disorders) Builds on prior support from The Michael J. Fox Foundation and further validates Lario’s precision neuroscience platform Edinburgh, UK – 19 February 2026 – Lario Therapeutics (“Lario” or the “Company”), a biopharmaceutical company developing […]

Read more
© Optimum Strategic Communications.